secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001297184-23-000057
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar completes $500M acquisition of BAQSIMI from Lilly; funds with $500M term loan
--------------------------------------------------------------------------------

- Paid $500M cash at closing; also owes $125M guaranteed payment in one year plus up to $450M contingent milestones.
- Entered $500M senior secured term loan (fully drawn) and $200M revolver (undrawn) to finance the deal.
- BAQSIMI is a branded intranasal glucagon for severe hypoglycemia; expands Amphastar's diabetes portfolio into 26 countries.
- Credit facilities mature June 30, 2028; interest rate initially Term SOFR + 2.25% or base rate + 1.25%.
- Lilly will provide manufacturing and transition services for up to 18 months post-close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000057/0001297184-23-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000057/amph-20230630x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-23-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer